MUSK and myasthenia gravis: In patients with MG, anti‐FcRn therapy is expected to lead to a significant reduction in the levels of various pathogenic IgG, including the anti‐AChR‐IgG and the anti‐muscle‐specific tyrosine kinase (MuSK)‐IgG, both of which have been identified as drivers of disease pathology in various subtypes of MG.1, 2